Status:
TERMINATED
Multicentre Trial to Evaluate the Safety and Efficacy of CP-316,311 in Major Depressive Disorder
Lead Sponsor:
Pfizer
Conditions:
Depressive Disorder, Major
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
A six week, fixed dose, double-blind, double-dummy, placebo, and active controlled, multicentre trial to evaluate the safety and efficacy of CP-316,311 in outpatients with major depressive disorder.
Detailed Description
This study was terminated on March 17th, 2006. The results of the primary analysis at the interim showed that the CP-316,311 group was not significantly different than the placebo on the primary endpo...
Eligibility Criteria
Inclusion
- Outpatients with DSM-IV major depressive disorder
Exclusion
- Women of child bearing potential
Key Trial Info
Start Date :
April 1 2005
Trial Type :
INTERVENTIONAL
End Date :
April 1 2006
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT00143091
Start Date
April 1 2005
End Date
April 1 2006
Last Update
March 24 2008
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Bellevue, Washington, United States
2
Pfizer Investigational Site
Seattle, Washington, United States
3
Pfizer Investigational Site
Moscow, Russia
4
Pfizer Investigational Site
Rostov-on-Don, Russia